ANGPTL4 and diabetes mellitus: We also apply POINT to the Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial data, finding promising rare variants in PCSK9, ANGPTL4 and CETP that may be associated with lipoprotein-related outcomes.